Lonza
Biologika, niedermolekulare APIs sowie Herstellung von Zell- und Gentherapien.
Lonza stellt von seinem Basler Standort aus Biologika, niedermolekulare Wirkstoffe sowie Zell- und Gentherapie her. Das Unternehmen beliefert Gesundheitssysteme, Labore, OEM-Partner oder regulierte Exportkunden in seinen aufgeführten Hauptmärkten.
- Type
- brand seeking distribution
- Location
- Basel, Switzerland
- Founded
- 1897
- Website
- lonza.com
- Categories
- Medizin- & Gesundheitsbedarf, Chemie & Kunststoffe
- Markets
- Schweiz, Vereinigte Staaten, Deutschland, Singapur
Verified facts
- certificate-page-on-site (amber), checked 2026-08-11 Company's own certification page
- domain-registered (green), checked 2026-08-02 Domain registry record
- web-presence-since (green), checked 2026-08-03 Internet Archive (Wayback)
- operating-permit (green), checked 2026-08-24 SHAB, Swiss Official Gazette of Commerce
- lei-active (green), checked 2026-07-21 GLEIF
- sanctions-clear (green), checked 2026-07-21 OpenSanctions
- registry-active-global (green), checked 2026-07-21 Zefix (Swiss commercial registry)
Claimed certifications
- Good Manufacturing Practice
- ISO 9001, Quality Management IAF CertSearch
Import rules for these goods
- Medical devices sold in the EU must carry CE marking under the Medical Device Regulation (EU) 2017/745, with a conformity assessment matched to the device risk class. European Commission (MDR)
- For the US market, the maker must have an FDA device establishment registration and product listing; most instruments also need 510(k) premarket clearance. US FDA (devices)